Author
Griffin, Billy | |
Franks, Jan | |
Hobbs, Melissa | |
KADLUBAR, FRED - NCTR | |
BRAND, C - NCTR |
Submitted to: Journal of Aquatic Animal Health
Publication Type: Peer Reviewed Journal Publication Acceptance Date: 7/21/1999 Publication Date: N/A Citation: N/A Interpretive Summary: To meet the needs of FDA in evaluating the human food safety of potassium permanganate as a disease treatment for fish, channel catfish were exposed to different concentrations of waterborne potassium permanganate for 12 weeks during which time liver and muscle samples samples were collected and analyzed for manganese content. The study was conducted under the auspices of the Good Laboratory Practices Act. The study showed that exposure to near lethal concentrations of potassium permanganate for 12 weeks did not alter liver or muscle concentrations of manganese. The conclusion from the study is that use of potassium permangaanate as a disease therapeutant in channal catfish poses no hazard to human consumers. Technical Abstract: To meet the needs of FDA in evaluating the human food safety of potassium permanganate as a disease treatment for fish, channel catfish were exposed to different concentrations of waterborne potassium permanganate for 12 weeks during which time liver and muscle samples samples were collected and analyzed for manganese content. The study was conducted under the auspices of the Good Laboratory Practices Act. The study showed that exposure to incipient lethal concentrations of potassium permanganate for 12 weeks did not alter liver or muscle concentrations of manganese. The conclusion from the study is that use of potassium permangaanate as a disease therapeutant in channal catfish poses no hazard to human consumers. |